MA32965B1 - Derives de sulfonamides - Google Patents

Derives de sulfonamides

Info

Publication number
MA32965B1
MA32965B1 MA34014A MA34014A MA32965B1 MA 32965 B1 MA32965 B1 MA 32965B1 MA 34014 A MA34014 A MA 34014A MA 34014 A MA34014 A MA 34014A MA 32965 B1 MA32965 B1 MA 32965B1
Authority
MA
Morocco
Prior art keywords
compounds
sulfonamide derivatives
preparation
tautomers
solvates
Prior art date
Application number
MA34014A
Other languages
Arabic (ar)
English (en)
Inventor
Serge Beaudoin
Michael Christopher Laufersweiler
Christopher John Markworth
Brian Edward Marron
David Simon Millan
David James Rawson
Steven Michael Reister
Kosuke Sasaki
Robert Ian Storer
Paul Anthony Stupple
Nigel Alan Swain
Christopher William West
Shulan Zhou
Original Assignee
Pfizer Ltd
Icagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41818828&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32965(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Ltd, Icagen Inc filed Critical Pfizer Ltd
Publication of MA32965B1 publication Critical patent/MA32965B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical
    • C07D263/50—Benzene-sulfonamido oxazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/18—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C07F9/6539—Five-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention porte sur des composés représentés par la formule (I) et des sels, solvates ou tautomères de ceux-ci pharmaceutiquement acceptables, sur des procédés pour la préparation de tels composés, sur des intermédiaires utilisés dans la préparation de tels composés et sur des compositions contenant de tels composés et sur les utilisations de tels composés, en particulier pour le traitement de la douleur.
MA34014A 2009-01-12 2010-01-06 Derives de sulfonamides MA32965B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14392009P 2009-01-12 2009-01-12
US24572609P 2009-09-25 2009-09-25
US25876009P 2009-11-06 2009-11-06
PCT/IB2010/050033 WO2010079443A1 (fr) 2009-01-12 2010-01-06 Dérivés sulfonamides

Publications (1)

Publication Number Publication Date
MA32965B1 true MA32965B1 (fr) 2012-01-02

Family

ID=41818828

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34014A MA32965B1 (fr) 2009-01-12 2010-01-06 Derives de sulfonamides

Country Status (41)

Country Link
US (3) US8153814B2 (fr)
EP (1) EP2385938B1 (fr)
JP (1) JP5053459B2 (fr)
KR (1) KR101345497B1 (fr)
CN (1) CN102348697B (fr)
AP (1) AP2811A (fr)
AR (1) AR075005A1 (fr)
AU (1) AU2010204118B2 (fr)
BR (1) BRPI1006128A2 (fr)
CA (1) CA2747419C (fr)
CL (1) CL2011001658A1 (fr)
CO (1) CO6400220A2 (fr)
CR (1) CR20110370A (fr)
CU (1) CU24099B1 (fr)
DK (1) DK2385938T3 (fr)
DO (1) DOP2011000218A (fr)
EA (1) EA020460B1 (fr)
EC (1) ECSP11011198A (fr)
ES (1) ES2536191T3 (fr)
GE (1) GEP20135992B (fr)
GT (1) GT201100195A (fr)
HN (1) HN2010000084A (fr)
HR (1) HRP20150355T1 (fr)
HU (1) HUE025013T2 (fr)
IL (1) IL213517A (fr)
MA (1) MA32965B1 (fr)
MX (1) MX2011007424A (fr)
MY (1) MY157017A (fr)
NI (1) NI201100137A (fr)
NZ (1) NZ593473A (fr)
PE (2) PE20120008A1 (fr)
PL (1) PL2385938T3 (fr)
PT (1) PT2385938E (fr)
RS (1) RS53941B1 (fr)
SV (1) SV2011003970A (fr)
TN (1) TN2011000316A1 (fr)
TW (2) TWI494317B (fr)
UA (1) UA105911C2 (fr)
UY (1) UY32379A (fr)
WO (1) WO2010079443A1 (fr)
ZA (1) ZA201105530B (fr)

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010011095A (es) * 2008-04-08 2010-11-05 Gruenenthal Gmbh Derivados de sulfonamidas sustituidos.
EA020460B1 (ru) * 2009-01-12 2014-11-28 Пфайзер Лимитед Производные сульфонамида
DE102009058280A1 (de) * 2009-12-14 2011-06-16 Merck Patent Gmbh Thiazolderivate
CA2789606A1 (fr) 2010-02-25 2011-09-01 Pfizer Limited Analogues peptidiques en tant qu'agonistes des recepteurs opioides
ES2532356T3 (es) * 2010-07-09 2015-03-26 Pfizer Limited N-sulfonilbenzamidas como inhibidores de los canales de sodio dependientes de voltaje
US9096558B2 (en) 2010-07-09 2015-08-04 Pfizer Limited N-sulfonylbenzamide compounds
ES2533065T3 (es) 2010-07-09 2015-04-07 Pfizer Limited Bencenosulfonamidas útiles como inhibidores de los canales de sodio
CA2804351A1 (fr) 2010-07-12 2012-01-19 Pfizer Limited Composes chimiques
ES2525581T3 (es) 2010-07-12 2014-12-26 Pfizer Limited Derivados de N-sulfonilbenzamida útiles como inhibidores del canal de sodio dependiente de voltaje
US9102621B2 (en) 2010-07-12 2015-08-11 Pfizer Limited Acyl sulfonamide compounds
WO2012007868A2 (fr) 2010-07-12 2012-01-19 Pfizer Limited Composés chimiques
CA2804877A1 (fr) 2010-07-12 2012-01-19 Pfizer Limited Composes chimiques
EP2616441B1 (fr) 2010-09-17 2019-08-07 Purdue Pharma L.P. Composés de pyridine et ses utilisations
CN103492575A (zh) 2011-01-18 2014-01-01 安姆根有限公司 NaV1.7敲除小鼠及其用途
WO2012120398A1 (fr) 2011-03-04 2012-09-13 Pfizer Limited Dérivés de carboxamide substitués par aryle en tant que modulateurs de trpm8
PE20141050A1 (es) 2011-04-05 2014-08-30 Pfizer Ltd Inhibidores de quinasa relacionados con pirrolo (2,3-d) pirimidina tropomiosina
TWI478908B (zh) * 2011-07-01 2015-04-01 Gilead Sciences Inc 作為離子通道調節劑之稠合雜環化合物
ES2564366T3 (es) 2011-07-13 2016-03-22 Pfizer Limited Análogos de encefalina
US9981918B2 (en) * 2011-08-30 2018-05-29 Chdi Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
JP5363636B2 (ja) * 2011-10-21 2013-12-11 ファイザー・リミテッド 新規な塩および医学的使用
JP2014532660A (ja) 2011-10-28 2014-12-08 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 電位作動型ナトリウムチャネルにおける選択活性を有するベンゾオキサゾリノン化合物
WO2013064983A1 (fr) 2011-10-31 2013-05-10 Xenon Pharmaceuticals Inc. Composés de benzènesulfonamide et leur utilisation en tant qu'agents thérapeutiques
EP2773641B1 (fr) 2011-10-31 2017-09-27 Xenon Pharmaceuticals Inc. Biaryléthersulfonamides et leur utilisation en tant qu'agents thérapeutiques
WO2013086229A1 (fr) 2011-12-07 2013-06-13 Amgen Inc. Inhibiteurs aryle et hétéroaryle bicycliques des canaux calciques
WO2013093688A1 (fr) 2011-12-19 2013-06-27 Pfizer Limited Dérivés sulfonamides et leur utilisation en tant qu'inhibiteurs de vgsc
CA2860553C (fr) 2012-01-04 2016-08-23 Pfizer Limited N-aminosulfonylbenzamides
US8889741B2 (en) * 2012-02-09 2014-11-18 Daiichi Sankyo Company, Limited Cycloalkane derivatives
WO2013161929A1 (fr) * 2012-04-26 2013-10-31 塩野義製薬株式会社 Dérivé de pyridinyl-morpholinone et composition médicamenteuse contenant celui-ci
WO2013161928A1 (fr) * 2012-04-26 2013-10-31 塩野義製薬株式会社 Dérivé oxazolotriazole et composition médicamenteuse contenant celui-ci
SG11201408284VA (en) 2012-05-22 2015-02-27 Xenon Pharmaceuticals Inc N-substituted benzamides and their use in the treatment of pain
AU2012382373A1 (en) 2012-06-12 2014-12-11 Abbvie Inc. Pyridinone and pyridazinone derivatives
US10071957B2 (en) 2012-07-06 2018-09-11 Genentech, Inc. N-substituted benzamides and methods of use thereof
EP2903986A1 (fr) 2012-10-04 2015-08-12 Pfizer Limited Inhibiteurs de kinases apparentés à la tropomyosine
JP2015531394A (ja) 2012-10-04 2015-11-02 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ ピロロ［２，３−ｄ］ピリミジントロポミオシン関連キナーゼ阻害剤
JP2015531395A (ja) 2012-10-04 2015-11-02 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ ピロロ［３，２−ｃ］ピリジントロポミオシン関連キナーゼ阻害剤
EP2906558B1 (fr) * 2012-10-15 2020-09-02 Daewoong Pharmaceutical Co., Ltd. Bloqueurs de canal sodique, leur procédé de préparation et leur utilisation
BR112015008987A2 (pt) 2012-10-26 2017-07-04 Merck Sharp & Dohme composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de uma composição farmacêutica
JO3225B1 (ar) * 2012-11-27 2018-03-08 Lilly Co Eli 6-((s)-1-{1-[5-(2-هيدروكسي-إيثوكسي)-بيريدين-2-يل]-1h-بيرازول-3-يل}إيثيل)-3h-1 ، 3-بنزو ثيازول-2- أون باعتباره مضاد مستقبل ampa يعتمد على tarp- جاما 8
UA112028C2 (uk) 2012-12-14 2016-07-11 Пфайзер Лімітед Похідні імідазопіридазину як модулятори гамка-рецептора
RU2015143906A (ru) 2013-03-14 2017-04-18 Дженентек, Инк. Замещенные триазолопиридины и способы их применения
BR112015022385A2 (pt) * 2013-03-14 2017-07-18 Daiichi Sankyo Co Ltd droga para uma doença respiratória
US9493429B2 (en) 2013-03-15 2016-11-15 Genentech, Inc. Substituted benzoxazoles and methods of use thereof
CA2900604A1 (fr) * 2013-03-15 2014-09-25 Chromocell Corporation Modulateurs du canal sodique pour le traitement de la douleur
CN112500338A (zh) 2013-03-15 2021-03-16 全球血液疗法股份有限公司 化合物及其用于调节血红蛋白的用途
EP2792360A1 (fr) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide pour utilisation dans le traitement de HCV
TW201512171A (zh) 2013-04-19 2015-04-01 Pfizer Ltd 化學化合物
TW201443025A (zh) 2013-04-19 2014-11-16 Pfizer Ltd 化學化合物
JP6026024B2 (ja) 2013-06-27 2016-11-16 ファイザー・インク 複素芳香族化合物およびそのドーパミンｄ１リガンドとしての使用
MX2016002974A (es) 2013-09-09 2016-06-02 Peloton Therapeutics Inc Eteres de arilo y sus usos.
AU2014318979B2 (en) 2013-09-10 2019-03-28 Chromocell Corporation Sodium channel modulators for the treatment of pain and diabetes
EA202092627A1 (ru) 2013-11-18 2021-09-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
AU2014356967A1 (en) 2013-11-27 2016-07-07 Genentech, Inc. Substituted benzamides and methods of use thereof
EP3083602A1 (fr) 2013-12-20 2016-10-26 Pfizer Limited Inhibiteurs de kinase apparentés à la n-acylpipéridine éther tropomyosine
US20170197939A1 (en) 2014-04-15 2017-07-13 Pfizer Inc. Tropomyosin-Related Kinase Inhibitors Containing Both A 1H-Pyrazole And A Pyrimidine Moiety
EP3140298A1 (fr) 2014-05-07 2017-03-15 Pfizer Inc. Inhibiteurs de kinases apparentées à la tropomyosine
CA2950393A1 (fr) 2014-05-30 2015-12-03 Pfizer Inc. Benzenesulfonamides utiles en tant qu'inhibiteurs des canaux sodiques
US9802945B2 (en) 2014-06-12 2017-10-31 Pfizer Limited Imidazopyridazine derivatives as modulators of the GABAA receptor activity
JP2017525677A (ja) 2014-07-07 2017-09-07 ジェネンテック， インコーポレイテッド 治療用化合物及びその使用方法
WO2016009296A1 (fr) 2014-07-16 2016-01-21 Pfizer Inc. Inhibiteurs de kinase liés à la n-acylpipéridine éther tropomyosine
KR20170026633A (ko) 2014-07-17 2017-03-08 씨에이치디아이 파운데이션, 인코포레이티드 Hiv-관련 장애의 치료 방법 및 치료용 조성물
WO2016009303A1 (fr) 2014-07-17 2016-01-21 Pfizer Inc. Associations de produits pharmaceutiques comprenant de la gabapentine ou de la prégabaline avec des inhibiteurs de nav1.7
WO2016020784A1 (fr) 2014-08-05 2016-02-11 Pfizer Inc. Inhibiteurs de kinases apparentées à la n-acylpyrrolidine éther tropomyosine
WO2016034971A1 (fr) 2014-09-04 2016-03-10 Pfizer Limited Dérivés sulfonamides utilisés en tant qu'inhibiteurs d'urat1
WO2016040315A1 (fr) * 2014-09-09 2016-03-17 Chromocell Corporation Inhibiteurs sélectifs de nav1.7 pour le traitement du diabète
WO2016067143A1 (fr) 2014-10-28 2016-05-06 Pfizer Inc. Composés n- (2-alkylèneimino-3-phénylpropyl)acétamide et leur utilisation contre la douleur et le prurit par inhibition des canaux trpa1
KR102412146B1 (ko) 2015-02-11 2022-06-22 주식회사 아이엔테라퓨틱스 소디움 채널 차단제
US10807948B2 (en) 2015-03-11 2020-10-20 Peloton Therapeutics, Inc. Aromatic compounds and uses thereof
EP3267792A4 (fr) 2015-03-11 2018-09-26 Peloton Therapeutics, Inc. Compositions utilisées pour traiter l'hypertension artérielle pulmonaire
EP3268362B1 (fr) 2015-03-11 2021-10-20 Peloton Therapeutics, Inc. Pyridines substituées et leurs utilisations
WO2016145045A1 (fr) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Compositions s'utilisant dans le traitement du glioblastome
WO2016168510A1 (fr) 2015-04-17 2016-10-20 Peloton Therapeutics, Inc. Thérapie combinée avec un inhibiteur de hif-2-alpha et un agent immunothérapeutique, et applications corresponantes
BR112017024853A2 (pt) 2015-05-22 2018-08-07 Genentech Inc composto, composição farmacêutica, método para tratar uma doença ou condição em um mamífero, para tratamento de prurido em um mamífero, para tratamento ou profilaxia e uso de um composto
US9932304B2 (en) * 2015-06-16 2018-04-03 University College Dublin, National University Of Ireland, Dublin Thromboxane receptor antagonists
MA42683A (fr) 2015-08-27 2018-07-04 Genentech Inc Composés thérapeutiques et leurs méthodes utilisation
SG10202007787RA (en) 2015-09-28 2020-09-29 Genentech Inc Therapeutic compounds and methods of use thereof
KR20180080187A (ko) * 2015-11-06 2018-07-11 다이이찌 산쿄 가부시키가이샤 디메톡시벤질기의 탈리 방법
MY194015A (en) * 2015-11-13 2022-11-08 Daewoong Pharmaceutical Co Ltd Sodium channel blocker
JP2018535234A (ja) 2015-11-25 2018-11-29 ジェネンテック， インコーポレイテッド ナトリウムチャネル遮断薬として有用な置換ベンズアミド
PL3386591T3 (pl) 2015-12-09 2021-02-22 Novartis Ag Heteroaromatyczne modulatory receptorów nmda i ich zastosowania
ES2950348T3 (es) 2015-12-09 2023-10-09 Novartis Ag Moduladores de receptores NMDA de tienopirimidinona y usos de los mismos
EP3386983A1 (fr) 2015-12-10 2018-10-17 Pfizer Limited Dérivés 4-(biphényl-3-yl)-1h-pyrazolo[3,4-c]pyridazine de formule (i) utilisés comme modulateurs de récepteur gaba pour le traitement de l'épilepsie et de la douleur
BR112018012327A2 (pt) 2015-12-18 2018-12-04 Merck Sharp & Dohme compostos de diamina-arilsulfonamida substituídos com hidroxialquilamina e hidroxicicloalquilamina com atividade seletiva em canais de sódio ativados por voltagem
CA3008614A1 (fr) 2015-12-18 2017-06-22 Merck Sharp & Dohme Corp. Composes d'arylsulfonamide a liaisons diamino-alkylamino ayant une activite selective vis-a-vis des canaux sodiques voltage-dependants
WO2017153952A1 (fr) * 2016-03-10 2017-09-14 Glaxosmithkline Intellectual Property Development Limited Dérivés de 5-sulfamoyl-2-hydroxybenzamide
US10442778B2 (en) 2016-03-22 2019-10-15 Merck Sharp & Dohme Corp. N1-phenylpropane-1,2-diamine compounds with selective activity in voltage-gated sodium channels
CN106397426A (zh) * 2016-03-29 2017-02-15 广东环境保护工程职业学院 一种1，3，4-噻二唑类化合物及其制备方法
CN106397425A (zh) * 2016-03-29 2017-02-15 广东环境保护工程职业学院 一种1,3,4-噻二唑类化合物及其制备方法
WO2017172802A1 (fr) 2016-03-30 2017-10-05 Genentech, Inc. Benzamides substitués et leurs méthodes d'utilisation
ES3022639T3 (en) 2016-05-20 2025-05-28 Xenon Pharmaceuticals Inc Benzenesulfonamide compounds and their use as therapeutic agents
WO2017202376A1 (fr) * 2016-05-26 2017-11-30 南京明德新药研发股份有限公司 Dérivé de sulfamide
SG11201903348UA (en) 2016-10-17 2019-05-30 Genentech Inc Therapeutic compounds and methods of use thereof
CN110325531B (zh) * 2016-12-09 2022-05-27 泽农医药公司 苯磺酰胺及其作为治疗剂的用途
EP3558318B1 (fr) 2016-12-22 2023-12-20 Novartis AG Modulateurs des récepteurs nmda et utilisations de ceux-ci
CN115124470B (zh) * 2017-03-23 2024-08-27 奥瑞基尼肿瘤有限公司 用于制备磺酰胺结构化的激酶抑制剂的方法
CN110546148A (zh) 2017-03-24 2019-12-06 基因泰克公司 作为钠通道抑制剂的4-哌啶-n-(嘧啶-4-基)色满-7-磺酰胺衍生物
CN111132961A (zh) * 2017-08-31 2020-05-08 拉夸里亚创药株式会社 作为ttx-s阻断剂的双芳氧基衍生物
EP3759098A1 (fr) 2018-02-26 2021-01-06 Genentech, Inc. Composés de pyridine-sulfonamide et leur utilisation contre la douleur et les états associés
CN111936494A (zh) 2018-03-30 2020-11-13 豪夫迈·罗氏有限公司 作为钠通道抑制剂的取代的氢-吡啶并-吖嗪
WO2019200369A1 (fr) * 2018-04-13 2019-10-17 Chromocell Corporation Composés et méthodes d'utilisation de composés pour la prévention ou le traitement de lésions des nerfs périphériques
TW202003490A (zh) * 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法
BR112020024729A2 (pt) 2018-06-13 2021-03-23 Xenon Pharmaceuticals, Inc. compostos de benzenossulfonamida e seu uso como agentes terapêuticos
GB201810092D0 (en) * 2018-06-20 2018-08-08 Ctxt Pty Ltd Compounds
RS64359B1 (sr) 2018-08-03 2023-08-31 Novartis Ag Heteroaromatični modulatori nmda receptora i njihove upotrebe
MA53488A (fr) 2018-08-31 2021-12-08 Xenon Pharmaceuticals Inc Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'inhibiteurs de canaux sodiques
IL279810B2 (en) 2018-08-31 2025-03-01 Xenon Pharmaceuticals Inc Heteroaryl-modified sulfonamide compounds and their use as medicinal agents
EP3891157A4 (fr) 2018-12-05 2022-08-31 Merck Sharp & Dohme Corp. Composés d'aryle sulfonamide substitués par 4-amino ou 4-alcoxy ayant une activité sélective dans des canaux sodiques sensibles à la tension
CN111285825B (zh) * 2018-12-10 2023-02-17 中国科学院上海药物研究所 一类苯磺酰胺取代的衍生物，其制法及其用途
WO2020248123A1 (fr) 2019-06-11 2020-12-17 Merck Sharp & Dohme Corp. Composés d'arylsulfonamide substitués par hydroxypyrrolidine ayant une activité sélective dans des canaux sodiques voltage-dépendants
CN112759559B (zh) * 2019-11-06 2022-08-12 成都康弘药业集团股份有限公司 作为钠通道阻滞剂的磺酰胺类化合物及其用途
CA3180846A1 (fr) * 2020-06-03 2021-12-09 Dana-Farber Cancer Institute, Inc. Inhibiteurs du domaine associe d'activation transcriptionnel (tead) et utilisations
CN114073698B (zh) * 2020-08-20 2023-03-31 山西泰睿鑫科技有限公司 一种止痛止痒药物组合物及其应用方法
CN112625030A (zh) * 2020-12-25 2021-04-09 杭州澳赛诺生物科技有限公司 一种一锅法合成n-保护3-溴代吡唑的合成方法
AU2023212996B2 (en) * 2022-01-28 2025-07-17 Rebel Medicine Inc Pharmaceutical compositions for treating pain
CN114288289A (zh) * 2022-02-17 2022-04-08 昆山彭济凯丰生物科技有限公司 具有镇痛和/或止痒功能的药物组合物及其应用
WO2024158653A2 (fr) * 2023-01-26 2024-08-02 Merck Sharp & Dohme Llc Composés d'indazole sulfonamide n-substitués à activité sélective dans le contexte de canaux sodiques voltage-dépendants
CN116239543B (zh) * 2023-03-17 2024-09-10 河南省农业科学院植物保护研究所 N-取代三唑磺酰胺类化合物及其用途
CN116283740B (zh) * 2023-03-27 2025-06-10 上海添泽生物医药有限公司 一种药物中间体的合成方法
WO2025137437A1 (fr) 2023-12-21 2025-06-26 Pfizer Inc. Formes solides d'un modulateur du récepteur gabaa et leurs procédés d'utilisation
US12234205B1 (en) 2024-05-22 2025-02-25 King Saud University Sulfonylhydrazide derivatives as anticancer agents

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3905971A (en) 1971-03-29 1975-09-16 Pfizer 2-Phenyl-as-triazine-3,5(2H,4H)diones
DE3531919A1 (de) 1985-09-07 1987-03-19 Hoechst Ag Substituierte 2-phenyl-hexahydro-1,2,4-triazin-3,5-dione, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung
DE3540654A1 (de) 1985-11-13 1987-05-14 Schering Ag Phenoxy-substituierte ss-carbolinderivate, ihre herstellung und ihre verwendung als arzneimittel
US5591761A (en) 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
JPH0264538A (ja) 1988-08-31 1990-03-05 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
EP0532239B1 (fr) 1991-09-10 1995-12-13 Zeneca Limited Dérivés de benzenesulfonamide comme inhibiteurs de 5-lipoxygenase
GB2263635A (en) 1992-01-28 1993-08-04 Merck & Co Inc Substitiuted triazoles as neurotensin antagonists
US5219856A (en) 1992-04-06 1993-06-15 E. I. Du Pont De Nemours And Company Angiotensin-II receptor blocking, heterocycle substituted imidazoles
NZ247440A (en) 1992-05-06 1995-04-27 Squibb & Sons Inc Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO1997046556A1 (fr) 1996-06-07 1997-12-11 Merck & Co., Inc. BENZENESULFONAMIDES D'OXADIAZOLE EN TANT QU'AGONISTES β3 SELECTIFS POUR LE TRAITEMENT DU DIABETE ET DE L'OBESITE
US6548524B2 (en) 1996-10-16 2003-04-15 American Cyanamid Company Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors
WO2000035298A1 (fr) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing-gum contenant des agents medicamenteux actifs
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
EP0937723A1 (fr) 1998-02-18 1999-08-25 Roche Diagnostics GmbH Nouveaux sulfonamides, procédé pour leur préparation et médicaments les contenant
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
EP1041072B1 (fr) 1999-03-31 2003-07-16 Pfizer Products Inc. Acides dioxocyclopentylhydroxamiques
HN2000000052A (es) 1999-05-28 2001-02-02 Pfizer Prod Inc Hidroxiamidas de acidos 3- (arilsulfonilamino)- tetrahidrofuran-3-carboxilicos.
BR0011539A (pt) 1999-05-28 2002-02-26 Pfizer Prod Inc Hidroxamidas de ácido 3-(arilsulfonilamino)-tetrahidropirano-3-carboxìlico
WO2001008674A1 (fr) 1999-07-29 2001-02-08 Ono Pharmaceutical Co., Ltd. Derives de sulfonamide et remedes pour l'allodynie
DE60020786T2 (de) 1999-09-30 2006-03-23 Pfizer Products Inc., Groton 6-Azauracilderivate als Liganden der Thyroidrezeptoren
US20020065303A1 (en) 2000-02-01 2002-05-30 Bing-Yan Zhu Bivalent phenylene inhibitors of factor Xa
WO2001087293A1 (fr) 2000-05-19 2001-11-22 Takeda Chemical Industries, Ltd. Inhibiteurs de la ?-secretase
EP1217000A1 (fr) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibiteurs du factor Xa et factor VIIa
JP2003081937A (ja) * 2001-09-07 2003-03-19 Bayer Ag ベンゼンスルホンアミド誘導体
AU2002347336A1 (en) 2001-12-05 2003-06-17 Astrazeneca Ab Quinoline derivatives
AU2002365057A1 (en) 2001-12-21 2003-07-30 Cytokinetics, Inc. Compositions and methods for treating heart failure
AU2003243921B2 (en) 2002-06-27 2009-05-07 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
AU2003268064A1 (en) 2002-08-09 2004-02-25 Astrazeneca Ab Oxadiazoles as modulators of metabotropic glutamate receptor-5
US7169797B2 (en) 2003-02-14 2007-01-30 Abbott Laboratories Protein-tyrosine phosphatase inhibitors and uses thereof
KR101109296B1 (ko) * 2003-03-24 2012-02-08 액시킨 파마수티컬스 인코포레이티드 천식 및 다른 염증성 또는 면역성 이상들의 치료용ｃｃｒ３ 길항 활성을 갖는 2-페녹시- 및2-페닐설폰아마이드 유도체
AU2004240885A1 (en) 2003-05-21 2004-12-02 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type I
EP1651595A2 (fr) 2003-05-30 2006-05-03 Rigel Pharmaceuticals, Inc. Inhibiteurs de ligase d'ubiquitine
WO2005000309A2 (fr) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Composes chimiques
EP1653952A4 (fr) 2003-08-06 2007-04-04 Pfizer Prod Inc Composes d'oxazole destines au traitement de troubles neurodegenerescents
KR20060073930A (ko) * 2003-08-08 2006-06-29 버텍스 파마슈티칼스 인코포레이티드 통증 치료시 나트륨 또는 칼슘 채널 차단제로서 유용한헤테로아릴아미노설포닐페닐 유도체
US7378414B2 (en) 2003-08-25 2008-05-27 Abbott Laboratories Anti-infective agents
ES2299906T3 (es) 2003-11-25 2008-06-01 Eli Lilly And Company Moduladores de receptores activados por proliferadores de peroxisomas.
ZA200605247B (en) 2003-12-15 2007-10-31 Japan Tobacco Inc N-substituted-n-sulfonylaminocyclopropane compounds and pharmaceutical use thereof
AP2006003771A0 (en) 2004-04-30 2006-10-31 Warner Lambert Co Substituted morpholine compounds for the treatmentof central nervous system disorders
DE602005004142T2 (de) 2004-05-24 2009-01-02 F. Hoffmann-La Roche Ag 4-hydroxy-4-methylpiperidin-1-carbonsäure-(4-methoxy-7-morpholin-4-ylbenzothiazol-2-yl)-amid
JP2008503591A (ja) 2004-06-22 2008-02-07 ライジェル ファーマシューティカルズ， インコーポレイテッド ユビキチンリガーゼ阻害剤
CA2573223C (fr) 2004-08-06 2013-05-21 Otsuka Pharmaceutical Co., Ltd. Compose aromatique
KR101231466B1 (ko) 2004-09-13 2013-02-07 오노 야꾸힝 고교 가부시키가이샤 질소 함유 복소환 유도체 및 이들을 유효 성분으로 하는약제
SE0402735D0 (sv) 2004-11-09 2004-11-09 Astrazeneca Ab Novel compounds
US20080015223A1 (en) 2004-12-03 2008-01-17 Arena Pharmaceuticals, Inc. Pyrazole Derivatives as Modulators of the 5-Ht2a Serotonin Receptor Useful for the Treatment of Disorders Related Thereto
DK2354126T3 (da) 2005-01-14 2014-01-13 Chemocentryx Inc Heteroarylsulfonamider og ccr2
US7301022B2 (en) 2005-02-15 2007-11-27 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US7816382B2 (en) 2005-06-27 2010-10-19 Bristol-Myers Squibb Company Linear urea mimics antagonists of P2Y1 receptor useful in the treatment of thrombotic condition
ATE485269T1 (de) 2005-06-27 2010-11-15 Bristol Myers Squibb Co C-verknüpfte zyklische antagonisten des p2y1- rezeptors mit eignung bei der behandlung thrombotischer leiden
RS20080118A (sr) 2005-09-23 2009-05-06 Pfizer Products Inc., Piridinaminosulfonil supstituisani benzamidi kao inhibitori citohroma p450 3a4 (cyp3a4)
CA2624726A1 (fr) 2005-10-06 2007-04-12 Sanofi-Aventis 4-oxy-n-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, procedes pour leur preparation et leur utilisation en tant que substances pharmaceutiques
EP1948597A1 (fr) 2005-10-21 2008-07-30 Vertex Pharmaceuticals Incorporated Derives modulant des canaux ioniques
AR058296A1 (es) 2005-12-09 2008-01-30 Kalypsys Inc Inhibidores de histona desacetilasa y composicion farmaceutica
RU2441869C2 (ru) 2005-12-21 2012-02-10 Эбботт Лэборетриз Противовирусные соединения
JP5089185B2 (ja) 2006-02-02 2012-12-05 大塚製薬株式会社 コラーゲン産生抑制剤。
BRPI0707427A2 (pt) 2006-02-03 2011-05-03 Lilly Co Eli composto ou um sal farmaceuticamente aceitável do mesmo, método para tratar dislipidemia, aterosclerose, e diabetes e complicações da mesma, para elevar os nìveis plásmicos de hdl, e para diminuir triglicerìdeos plásmicos, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo
US8383641B2 (en) 2006-04-14 2013-02-26 Abbott Gmbh & Co. Kg Aryloxyethylamine compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
GB0608386D0 (en) 2006-04-27 2006-06-07 Senexis Ltd Compounds
WO2008002490A2 (fr) 2006-06-23 2008-01-03 Radius Health, Inc. Traitement de symptômes vasomoteurs par des modulateurs des récepteurs d'œstrogène sélectifs
AU2007307990A1 (en) 2006-10-05 2008-04-17 Janssen Pharmaceutica, N.V. Heterocyclic derived metalloprotease inhibitors
WO2008046216A1 (fr) 2006-10-18 2008-04-24 Methylgene, Inc. Inhibiteurs de kinase et leurs utilisations
SI2076508T1 (sl) 2006-10-18 2011-04-29 Pfizer Prod Inc Spojine biaril eter sečnine
WO2008050200A1 (fr) 2006-10-24 2008-05-02 Pfizer Products Inc. Composés d'oxadiazole comme antagonistes des canaux calciques
WO2008057280A1 (fr) 2006-10-27 2008-05-15 Amgen Inc. Composés à cycles multiples et procédés d'utilisation
EP2139852A1 (fr) 2006-12-19 2010-01-06 Pharmos Corporation Dérivés sulfonamides avec indications thérapeutiques
EP2125781A2 (fr) 2006-12-20 2009-12-02 Amgen Inc. Hétérocycles substitués et leurs méthodes d'utilisation
JP2008214222A (ja) 2007-03-01 2008-09-18 Tokyo Medical & Dental Univ フェノール誘導体及びその医薬用途
JP5361857B2 (ja) * 2007-03-23 2013-12-04 ファイザー・リミテッド イオンチャネルの阻害剤
ES2323927B1 (es) 2007-03-30 2010-05-14 Laboratorios Salvat, S.A. Metodo in vitro no invasivo para detectar carcinoma transicional de vejiga.
US7960567B2 (en) 2007-05-02 2011-06-14 Amgen Inc. Compounds and methods useful for treating asthma and allergic inflammation
WO2008135826A2 (fr) 2007-05-03 2008-11-13 Pfizer Limited Dérivés de la pyridine
US7592342B2 (en) 2007-05-10 2009-09-22 Smithkline Beecham Corporation Quinoxaline derivatives as PI3 kinase inhibitors
WO2009012242A2 (fr) 2007-07-13 2009-01-22 Icagen, Inc. Inhibiteurs des canaux sodiques
WO2009011850A2 (fr) 2007-07-16 2009-01-22 Abbott Laboratories Nouveaux composés thérapeutiques
EP2220065A2 (fr) 2007-07-30 2010-08-25 Encysive Pharmaceuticals, Inc. Modulateurs du recepteur ccr9 et procedes de leur utilisation
JP5544296B2 (ja) 2007-11-16 2014-07-09 ライジェル ファーマシューティカルズ， インコーポレイテッド 代謝障害のためのカルボキサミド、スルホンアミド、およびアミン化合物
MX2010011258A (es) 2008-04-14 2011-06-20 Univ Texas Inhibidores de molecula pequeña del dominio de homologia de pleckstrin y metodos para usar los mismos.
CA2721452A1 (fr) 2008-04-16 2009-10-22 Biolipox Ab Composes bis-aryliques destines a etre utilises en tant que medicaments
EA020460B1 (ru) * 2009-01-12 2014-11-28 Пфайзер Лимитед Производные сульфонамида

Also Published As

Publication number Publication date
US20100197655A1 (en) 2010-08-05
EP2385938B1 (fr) 2015-03-04
GEP20135992B (en) 2013-12-25
US8541588B2 (en) 2013-09-24
AP2811A (en) 2013-12-31
AU2010204118B2 (en) 2012-12-20
PT2385938E (pt) 2015-06-02
EA020460B1 (ru) 2014-11-28
GT201100195A (es) 2013-12-10
US20130338111A1 (en) 2013-12-19
AR075005A1 (es) 2011-03-02
NZ593473A (en) 2013-02-22
CA2747419A1 (fr) 2010-07-15
EP2385938A1 (fr) 2011-11-16
UY32379A (es) 2010-08-31
TN2011000316A1 (fr) 2012-12-17
TWI419897B (zh) 2013-12-21
US8907101B2 (en) 2014-12-09
ECSP11011198A (es) 2011-10-31
US20120149679A1 (en) 2012-06-14
IL213517A0 (en) 2011-07-31
CU20110145A7 (es) 2012-02-15
CN102348697B (zh) 2014-12-10
PE20142099A1 (es) 2014-12-13
SV2011003970A (es) 2012-01-03
HN2010000084A (es) 2011-12-05
EA201170922A1 (ru) 2012-01-30
TW201422631A (zh) 2014-06-16
MY157017A (en) 2016-04-15
PE20120008A1 (es) 2012-01-24
AU2010204118A1 (en) 2011-07-07
IL213517A (en) 2015-11-30
CR20110370A (es) 2011-07-21
JP5053459B2 (ja) 2012-10-17
TW201038586A (en) 2010-11-01
WO2010079443A1 (fr) 2010-07-15
ZA201105530B (en) 2012-12-27
PL2385938T3 (pl) 2015-07-31
HRP20150355T1 (hr) 2015-06-19
KR20110104558A (ko) 2011-09-22
AP2011005788A0 (en) 2011-08-31
HUE025013T2 (hu) 2016-04-28
JP2012515156A (ja) 2012-07-05
UA105911C2 (uk) 2014-07-10
BRPI1006128A2 (pt) 2016-11-01
KR101345497B1 (ko) 2013-12-31
CN102348697A (zh) 2012-02-08
TWI494317B (zh) 2015-08-01
US8153814B2 (en) 2012-04-10
ES2536191T3 (es) 2015-05-21
CA2747419C (fr) 2014-07-08
CO6400220A2 (es) 2012-03-15
CU24099B1 (es) 2015-06-30
DOP2011000218A (es) 2011-10-15
RS53941B1 (sr) 2015-08-31
NI201100137A (es) 2011-11-02
CL2011001658A1 (es) 2011-11-11
HK1161253A1 (en) 2012-08-24
MX2011007424A (es) 2011-08-12
DK2385938T3 (en) 2015-04-27

Similar Documents

Publication Publication Date Title
MA32965B1 (fr) Derives de sulfonamides
TN2009000450A1 (fr) Derives de pyridine
TNSN07022A1 (fr) Derives de pyridine
MA29926B1 (fr) Derives de pyrazine
MA31754B1 (fr) Cis-imidazolines chirales
MA30911B1 (fr) Nouveaux derives de sulfonamide en tant qu'antagonistes de bradykinine
MA29791B1 (fr) Composes therapeutiques.
MA32466B1 (fr) Derives de triazole utiles pour le traitement de maladies
MA30629B1 (fr) Derives de pyrazole servant d'inhibiteurs du cytochrome p450
MA33304B1 (fr) Indazoles substitués par oxazole comme inhibiteurs de pi3-kinase
TN2014000147A1 (fr) Derives de (4-phenylimidazol-2-yl) ethylamine utiles comme modulateurs de canal sodique
MA35601B1 (fr) Pyrrolotriazines substituées par hydroxyméthylaryle utilisées comme inhibiteurs d'alk1
MA32171B1 (fr) Compose heterocyclique
MA35128B1 (fr) Nouveaux dérivés d'imidazole utiles pour le traitement de l'arthrite
MA33642B1 (fr) Composés chimiques
MA33636B1 (fr) Dérivés aminopropioniques substitués comme inhibiteurs de néprilysine
MA40225A (fr) Composés dihydroisoquinolinone substitués
MA31170B1 (fr) Dérivés de 2-amino-5,7-dihydro-6h-pyrrolo[3,4-d]pyrimidine servant d'inhibiteurs de la hsp-90 pour le traitement du cancer
MA45782B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
TN2009000524A1 (en) Novel dicarboxylic acid derivatives as s1p1 receptor agonists
MA56883B1 (fr) Dérivés de 2-hydroxycycloalcane-1-carbamoyle
MX2010009995A (es) Heterociclos puenteados como inhibidores de la integrasa del virus de inmunodeficiencia humana.
MA46229B1 (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
MA31710B1 (fr) (carboxylalkylenephenyl)phényloxamides, procédés pour la production de ceux-ci et utilisation de ceux-ci en tant que medicament
MA35749B1 (fr) Dérivés nucléosidiques 4'-azido, 3'-fluoro substitués en tant qu'inhibiteurs de la réplication de l'arn du vhc